All In Biotech

Drug Trial Radar · NCT03694249

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

A Pilot Trial of Ifetroban, A Thromboxane A2 Receptor Antagonist, in Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

Last checked: Nov 19, 2026Latest source record: Jun 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Actual

Start

Dec 12, 2018

Primary completion

Apr 2025

Study completion Apr 2026

Sponsor

Lead sponsor
Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cumberland Pharmaceuticals
First posted
Oct 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment and spreading throughout the body. Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.

Conditions

  • Malignant Solid Tumor

Interventions

  • Ifetroban SodiumDrug

    Given by mouth

  • PlaceboOther

    Given by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: Up to 30 days after completing treatment
  2. Adherence to treatment (participants will be provided a pill diary to record when they take their medication. Study staff will collect the pill diary from participants at their clinic visits).Time frame: Up to 12 months
  3. Summarized change of FACT-G score (scale = 0 to 4)Time frame: Up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.